Boston—Artificial intelligence and machine learning could improve the ability to predict venous thromboembolism (VTE) in cancer patients over the current gold-standard approaches, according to a research grant award presentation at the 2022 Hematology/Oncology Pharmacy Association (HOPA) annual conference.
VTE, including both deep vein thrombosis and pulmonary embolism, represents a major source of morbidity and mortality for cancer patients, with an incidence ranging from 1%